Other Chinese News

4 May 1997

- Over 50 Chinese or foreign-funded drug firms have invested $361million in the Pudong New Area of east Shanghai, including Xian Feng, Xin Ya, Sine and Roche. By 2000, output from the Pudong area is expected to reach $1.2 billion.

The No 3 Shanghai pharmaceutical factory has already made a large investment to establish Shanghai Xian Feng, while Xin Ya produces mainly vitamin B6. Roche is the largest foreign presence, with a $45 million joint venture, Shanghai Roche, which has started the manufacture and marketing of antibiotics, vaccines, anticancer agents and vitamins.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight